{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:58:43Z","timestamp":1774911523752,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,30]]},"DOI":"10.7759\/cureus.106153","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:33:50Z","timestamp":1774910030000},"source":"Crossref","is-referenced-by-count":0,"title":["From Cost to Value: A Comparative Analysis of Medical and Surgical Management of Inflammatory Bowel Disease in a Public Referral Hospital in Mexico"],"prefix":"10.7759","author":[{"given":"Angie Eleoneai","family":"Vargas Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samanta Kin","family":"Dosal Lim\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Yazmin","family":"L\u00f3pez P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rosales T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Billy","family":"Jim\u00e9nez Bobadilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma Rosa","family":"S\u00e1nchez Conejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertha Alicia","family":"Mancilla Salcedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso David","family":"Aparicio Bola\u00f1os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Luis","family":"De Le\u00f3n Rend\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng SC","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al.. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017, 390:2769-2778. 10.1016\/S0140-6736(17)32448-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: from 2015 to 2025","volume":"12","author":"Kaplan GG","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015, 12:720-727. 10.1038\/nrgastro.2015.150","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30012-1","article-title":"Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study","volume":"5","author":"Burisch J","year":"2020","unstructured":"Burisch J, Vardi H, Schwartz D, et al.. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020, 5:454-464. 10.1016\/S2468-1253(20)30012-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.06.049","article-title":"The cost of inflammatory bowel disease care: how to make it sustainable","volume":"23","author":"Burisch J","year":"2025","unstructured":"Burisch J, Claytor J, Hernandez I, Hou JK, Kaplan GG. The cost of inflammatory bowel disease care: how to make it sustainable. Clin Gastroenterol Hepatol. 2025, 23:386-395. 10.1016\/j.cgh.2024.06.049","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-024-04711-x","article-title":"Global, regional, and national burden of inflammatory bowel disease, 1990-2021: insights from the global burden of disease 2021","volume":"39","author":"Lin D","year":"2024","unstructured":"Lin D, Jin Y, Shao X, et al.. Global, regional, and national burden of inflammatory bowel disease, 1990-2021: insights from the global burden of disease 2021. Int J Colorectal Dis. 2024, 39:139. 10.1007\/s00384-024-04711-x","journal-title":"Int J Colorectal Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00003-1","article-title":"The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology and Hepatology Commission","volume":"8","author":"Burisch J","year":"2023","unstructured":"Burisch J, Zhao M, Odes S, et al.. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology and Hepatology Commission. Lancet Gastroenterol Hepatol. 2023, 8:458-492. 10.1016\/S2468-1253(23)00003-1","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.09.012","article-title":"Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults","volume":"135","author":"Kappelman MD","year":"2008","unstructured":"Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008, 135:1907-1913. 10.1053\/j.gastro.2008.09.012","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2025.08.013","article-title":"Cost-effectiveness and cost only studies for inflammatory bowel disease surgery: a scoping review","volume":"315","author":"Leeds IL","year":"2025","unstructured":"Leeds IL, Dill-Macky A, Prien C, Li H, Lincango E, Cohen BC, Holubar SD. Cost-effectiveness and cost only studies for inflammatory bowel disease surgery: a scoping review. J Surg Res. 2025, 315:1029-1038. 10.1016\/j.jss.2025.08.013","journal-title":"J Surg Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00284-4","article-title":"Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America","volume":"9","author":"Balderramo D","year":"2024","unstructured":"Balderramo D, Quaresma AB, Olivera PA, et al.. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024, 9:263-272. 10.1016\/S2468-1253(23)00284-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820931739","article-title":"Review of the epidemiology and burden of ulcerative colitis in Latin America","volume":"13","author":"Kotze PG","year":"2020","unstructured":"Kotze PG, Steinwurz F, Francisconi C, Zaltman C, Pinheiro M, Salese L, de Leon DP. Review of the epidemiology and burden of ulcerative colitis in Latin America. Ther Adv Gastroenterol. 2020, 13:10.1177\/1756284820931739","journal-title":"Ther Adv Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2025.502532","article-title":"Epidemiology and healthcare resource utilization in inflammatory bowel disease in Colombia between 2017 and 2021: a retrospective claims database study","volume":"49","author":"Juliao-Ba\u00f1os F","year":"2026","unstructured":"Juliao-Ba\u00f1os F, Parra-Izquierdo V, Pacheco-P\u00e1ez T, Lea\u00f1o JTA. Epidemiology and healthcare resource utilization in inflammatory bowel disease in Colombia between 2017 and 2021: a retrospective claims database study. Gastroenterol Hepatol. 2026, 49:502532. 10.1016\/j.gastrohep.2025.502532","journal-title":"Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2009.232","article-title":"The pharmacoeconomics of biologic therapy for IBD","volume":"7","author":"Cohen RD","year":"2010","unstructured":"Cohen RD. The pharmacoeconomics of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010, 7:103-109. 10.1038\/nrgastro.2009.232","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251318032","article-title":"Quality of life and burden of disease in a Mexican population with inflammatory bowel disease: an analysis of the RISE-MX trial","volume":"18","author":"Miranda-Cordero RM","year":"2025","unstructured":"Miranda-Cordero RM, Bosques-Padilla FJ, Mart\u00ednez-V\u00e1zquez MA, Barajas-Maldonado C, Rodriguez-Mendoza MM, Yamamoto-Furusho JK. Quality of life and burden of disease in a Mexican population with inflammatory bowel disease: an analysis of the RISE-MX trial. Ther Adv Gastroenterol. 2025, 18:10.1177\/17562848251318032","journal-title":"Ther Adv Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The burden of inflammatory bowel disease in Europe in 2020","volume":"15","author":"Zhao M","year":"2021","unstructured":"Zhao M, G\u00f6nczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021, 15:1573-1587. 10.1093\/ecco-jcc\/jjab029","journal-title":"J Crohns Colitis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19 Suppl A","author":"Silverberg MS","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T, et al.. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005, 19 Suppl A:5A-36A. 10.1155\/2005\/269076","journal-title":"Can J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"TR SC","year":"1955","unstructured":"TR SC, WI LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955, 2:1041-1048. 10.1136\/bmj.2.4947.1041","journal-title":"Br Med J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder KW","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987, 317:1625-1629. 10.1056\/NEJM198712243172603","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.2.174","article-title":"Microscopic activity in ulcerative colitis: what does it mean?","volume":"32","author":"Riley SA","year":"1991","unstructured":"Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean?. Gut. 1991, 32:174-178. 10.1136\/gut.32.2.174","journal-title":"Gut"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner D","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al.. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021, 160:1570-1583. 10.1053\/j.gastro.2020.12.031","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine T","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al.. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022, 16:2-17. 10.1093\/ecco-jcc\/jjab178","journal-title":"J Crohns Colitis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"18","author":"Gordon H","year":"2024","unstructured":"Gordon H, Minozzi S, Kopylov U, et al.. ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment. J Crohns Colitis. 2024, 18:1531-1555. 10.1093\/ecco-jcc\/jjae091","journal-title":"J Crohns Colitis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx061","article-title":"ECCO-ESCP consensus on surgery for Crohn's disease","volume":"12","author":"Bemelman WA","year":"2018","unstructured":"Bemelman WA, Warusavitarne J, Sampietro GM, et al.. ECCO-ESCP consensus on surgery for Crohn's disease. J Crohns Colitis. 2018, 12:1-16. 10.1093\/ecco-jcc\/jjx061","journal-title":"J Crohns Colitis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment","volume":"16","author":"Spinelli A","year":"2022","unstructured":"Spinelli A, Bonovas S, Burisch J, et al.. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment. J Crohns Colitis. 2022, 16:179-189. 10.1093\/ecco-jcc\/jjab177","journal-title":"J Crohns Colitis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael K","year":"2022","unstructured":"Papamichael K, Afif W, Drobne D, et al.. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022, 7:171-185. 10.1016\/S2468-1253(21)00223-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01836-7","article-title":"Global evolving patterns and cross-country inequalities of inflammatory bowel disease burden from 1990 to 2019: a worldwide report","volume":"73","author":"Cao L","year":"2024","unstructured":"Cao L, Dayimu A, Guan X, et al.. Global evolving patterns and cross-country inequalities of inflammatory bowel disease burden from 1990 to 2019: a worldwide report. Inflamm Res. 2024, 73:277-287. 10.1007\/s00011-023-01836-7","journal-title":"Inflamm Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.06.030","article-title":"Global hospitalization trends for Crohn\u2019s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses","volume":"21","author":"Buie MJ","year":"2023","unstructured":"Buie MJ, Quan J, Windsor JW, et al.. Global hospitalization trends for Crohn\u2019s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol. 2023, 21:2211-2221. 10.1016\/j.cgh.2022.06.030","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2022-0034","article-title":"Exploring work productivity loss in patients with inflammatory bowel disease","volume":"9","author":"Nasr S","year":"2023","unstructured":"Nasr S, Dahmani W, Jaziri H, et al.. Exploring work productivity loss in patients with inflammatory bowel disease. Future Sci OA. 2023, 9:FSO872. 10.2144\/fsoa-2022-0034","journal-title":"Future Sci OA"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2174\/1574887117666220811143426","article-title":"Quality of life in inflammatory bowel diseases (IBDs) patients after surgery","volume":"17","author":"Di Candido F","year":"2022","unstructured":"Di Candido F. Quality of life in inflammatory bowel diseases (IBDs) patients after surgery. Rev Recent Clin Trials. 2022, 17:227-239. 10.2174\/1574887117666220811143426","journal-title":"Rev Recent Clin Trials"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"120","author":"Lichtenstein GR","year":"2025","unstructured":"Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, Ha CY. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2025, 120:1225-1264. 10.14309\/ajg.0000000000003465","journal-title":"Am J Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet L","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, et al.. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015, 110:1324-1338. 10.1038\/ajg.2015.233","journal-title":"Am J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/472853-from-cost-to-value-a-comparative-analysis-of-medical-and-surgical-management-of-inflammatory-bowel-disease-in-a-public-referral-hospital-in-mexico","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T22:33:52Z","timestamp":1774910032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/472853-from-cost-to-value-a-comparative-analysis-of-medical-and-surgical-management-of-inflammatory-bowel-disease-in-a-public-referral-hospital-in-mexico"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.106153","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}